Robin Hayes
TGA Greenlights Alzheimer’s Drug Donanemab for Early-Stage Patients
Australia’s Therapeutic Goods Administration (TGA) has officially approved donanemab, a monoclonal antibody therapy, for use in people with early-stage Alzheimer’s disease. Developed by pharmaceutical company Eli Lilly, donanemab has already secured approval in the United States and other jurisdictions. Its entry into the Australian market marks a significant milestone in dementia care—offering the first disease-modifying treatment option for individuals in the initial phase of Alzheimer’s.
· 4 min read